Gossamer Files NDA for Seralutinib in PAH
Gossamer Bio submitted a New Drug Application for seralutinib in pulmonary arterial hypertension to the FDA in September. The positive regulatory milestone and a structured private placement provide over $100 million in additional committed capital.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed